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Role of the Sensory Neuron Cytoskeleton in
Second Messenger Signaling for Inflammatory Pain
3 days, causes a switch in second messenger signaling
in response to a subsequent exposure to PGE2, a phe-
nomenon we refer to as hyperalgesic priming (Aley et
Olayinka A. Dina, Gordon C. McCarter,
Catherine de Coupade, and Jon D. Levine*
Department of Medicine
Department of Oral and Maxillofacial Surgery al., 2000). In carrageenan-primed paws, hyperalgesia
caused by PGE2, like that produced by EPI in carra-Division of Neuroscience and Biomedical Sciences
Program geenan-naive male rats, uses the PKA and PKC signal-
ing pathways (Aley et al., 2000), while ERK has not yetNIH Pain Center (UCSF)
University of California, San Francisco been evaluated.
Signaling by the 2-adrenergic receptor, throughSan Francisco, California 94143
which EPI acts to produce hyperalgesia (Aley et al.,
2001; Dina et al., 2001a; Khasar et al., 1999b), has been
shown to be dependent on an intact cytoskeleton (BlochSummary
et al., 2001; Calaghan et al., 2001; Wang et al., 2000).
Furthermore, second messenger systems that mediateProstaglandin E2 (PGE2) and epinephrine act directly
on nociceptors to produce mechanical hyperalgesia the effects of 2-adrenergic receptor activation, such as
PKA and PKC, have also been shown to require anthrough protein kinase A (PKA) alone or through a
combination of PKA, protein kinase C epsilon (PKC), intact cytoskeleton for signaling (Ahn et al., 1999; Cao
et al., 1999; Hough et al., 1994; Keenan and Kelleher,and extracellular signal-regulated kinase (ERK), re-
spectively. Disruptors of the cytoskeleton (microfila- 1998; Prekeris et al., 1998; Wang et al., 2000). We there-
fore studied the role of the sensory neuron cytoskeletonments, microtubules, and intermediate filaments)
markedly attenuated the hyperalgesia in rat paws in mechanical hyperalgesia induced in vivo in rat paws
by two inflammatory mediators that act at G protein-caused by injection of epinephrine or its downstream
mediators. In contrast, the hyperalgesia induced by coupled receptors and in sensitization of dorsal root
ganglion (DRG) neurons in vitro. Using disruptors orPGE2 or its mediators was not affected by any of the
cytoskeletal disruptors. These effects were mimicked stabilizers of the three major structural components of
the cytoskeleton—microfilaments, microtubules, and in-in vitro, as measured by enhancement of the tetrodo-
toxin-resistant sodium current. When PGE2 hyperalge- termediate filaments—we tested the dependence of re-
ceptor activation-induced second messenger signalingsia was shifted to dependence on PKC and ERK as
well as PKA, as when the tissue is “primed” by prior on an intact cytoskeleton. We also tested whether
changes that occur in second messenger mediation oftreatment with carrageenan, it too became dependent
on an intact cytoskeleton. Thus, inflammatory media- PGE2 signaling after hyperalgesic priming (Aley et al.,
2000) are accompanied by changes in dependence ontor-induced mechanical hyperalgesia was differen-
tially dependent on the cytoskeleton such that cy- the cytoskeleton.
toskeletal dependence correlated with mediation by
PKC and ERK. Results
Introduction Microfilaments
To examine the role of microfilaments in hyperalgesia
Inflammatory mediators, acting through G protein-cou- induced by direct-acting inflammatory agents, we in-
pled receptors (GPCRs), sensitize the peripheral termi- jected intradermally in the dorsum of the hindpaws of
nals of primary afferent nociceptors to cause a decrease rats the actin microfilament-disrupting agents cytocha-
in pain threshold (Gold et al., 1998; Gold, 1999; Rathee lasin B (CB), cytochalasin D (CD), latrunculin A (LatA),
et al., 2002; Southall and Vasko, 2001). Intracellular sig- or latrunculin B (LatB) 30 min prior to the injection of
naling downstream from these receptors can occur in the direct-acting hyperalgesic agents epinephrine (EPI)
various situations via any of three second messenger or prostaglandin E2 (PGE2). All of the disrupting agents
systems: cAMP/protein kinase A (PKA) (Aley et al., 2001; resulted in marked attenuation of EPI-induced hyperal-
Khasar et al., 1999b; Koda and Mizumura, 2002), protein gesia (all p  0.0001; Figure 1A) but had no effect on
kinase C (PKC) (Aley et al., 2001; Cesare et al., 1999; PGE2-induced hyperalgesia (all p  0.05; Figure 1B).
Dina et al., 2001a, 2001b; Khasar et al., 1999a), or extra- To confirm that the appropriate dose of microfilament-
cellular signal-regulated kinase (ERK) (Aley et al., 2001; disrupting agent was used, we injected one of the
Dina et al., 2001a; Gutkind, 2000). For example, prosta- agents, latrunculin A, in several doses for both forms of
glandin E2 (PGE2)-induced hyperalgesia is mediated by hyperalgesia. A clear dose-response relationship was
PKA alone, while epinephrine (EPI)-induced hyperalge- seen in the effect of latrunculin A (1 ng to 1 g per 2.5
sia is mediated by all three second messengers systems l) on EPI-induced hyperalgesia, while it did not affect
(Aley et al., 2001; Dina et al., 2001a). PGE2-induced hyperalgesia or baseline nociception at
Prior exposure to carrageenan, an inflammatory stim- any dose tested (Figure 1C). To confirm that the inhibi-
ulus that produces hyperalgesia lasting approximately tion of EPI hyperalgesia by cytochalasins or latrunculins
was due to actin disruption, we tested whether phalloi-
din could prevent cytochalasin D-induced loss of EPI*Correspondence: levine@itsa.ucsf.edu
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Figure 1. Role of Actin Filaments in Hyperal-
gesic Signaling
(A) The effect of disrupting actin filaments
with cytochalasin B (EPICB; n  6), cyto-
chalasin D (EPICD; n  12), latrunculin A
(EPILatA; n 6), or latrunculin B (EPILatB;
n  6) on mechanical hyperalgesia induced
by the direct-acting agent epinephrine (EPI;
n  16).
(B) The effect of disrupting actin filaments
with CB, CD, LatA, or LatB on mechanical
hyperalgesia induced by the direct-acting
agent prostaglandin E2 (PGE2; n 16). Values
of n for PGE2CB, PGE2CD, PGE2LatA,
and PGE2LatB are as with EPI  the same
agent in (A). Baseline paw withdrawal thresh-
old (110.7  0.6, g  SEM) was not affected
by actin disruptors, CB (n  12), CD (n  18),
LatA (n  12), or LatB (n  12).
(C) Dose-response relation of effects of LatA
on hyperalgesia induced by EPI (n  6 for
each dose) and PGE2 (n  6 for each dose).
(D) Stabilization of actin cytoskeleton by a
prior injection of rat paws with the actin fila-
ment stabilizer phalloidin blocked the attenu-
ating effect of the microfilament disruptor cy-
tochalasin D (PHACDEPI; n  6) on
epinephrine-induced hyperalgesia. The sta-
bilizer was injected 1 hr preceding the dis-
ruptor. Injection of the disruptor was followed
after 30 min by an injection of epinephrine
(EPI; n 12). Phalloidin by itself had no effect
on EPI- (EPIPHA; n  12) or PGE2-induced
hyperalgesia (not shown) or on baseline paw
withdrawal threshold (PHA; n  18).
(E) Disrupting actin filaments also blocks the
increase in the TTX-resistant sodium current
caused by epinephrine in whole-cell patch-
clamp experiments. After establishing the
whole-cell recording configuration, cells were
perfused with either 5 M latrunculin A in nor-
mal bath (latrunculin, n  5) or bath alone
(control, n  5) for 10–15 min. Epinephrine
(1 M) was then perfused via the bath for 3 min starting at time 0. Currents were normalized to the mean amplitude of the 9 baseline responses
before the application of epinephrine. The increase in TTX-R INa caused by epinephrine was significantly attenuated by pretreatment with
latrunculin A (p  0.05, two-way repeated measures ANOVA).
(F) Disrupting actin filaments had no effect on potentiation of TTX-R INa by PGE2. Experiments were performed exactly as in (E) with 1 M
PGE2 replacing epinephrine (latrunculin, n  6; control, n  7). Scale of the y axis is expanded relative to (E), since the average increase in
TTX-R INa in response to PGE2 is smaller than in response to epinephrine, due to the fact that only 50% of cells expressing TTX-R INa respond
to PGE2 while 80% respond to epinephrine (Gold et al., 1996; Khasar et al., 1999b).
In (A)–(D), all injections were made intradermally into the dorsum of the hindpaws. Each agent (disruptor or stabilizer) was injected 30 min
preceding the administration of EPI or PGE2 at the same site. Data is expressed as percentage change in the nociceptive threshold in grams
(%  SEM). (*p  0.0001; one-way ANOVA and Fisher’s PLSD post hoc test; NS  not significant).
hyperalgesia. Administration of phalloidin 1 hr preceding 1996). We tested whether the potentiation of TTX-R INa
by epinephrine or PGE2 was differentially dependent oninjection of cytochalasin D, followed after 30 min by an
injection of EPI, significantly prevented the cytocha- intact actin filaments, similar to epinephrine- and PGE2-
induced hyperalgesia in vivo. Exposure of cultured DRGlasin-D-induced attenuation of EPI hyperalgesia (p 
0.0001; Figure 1D). By itself, stabilization of actin fila- neurons to 5 M latrunculin A in the perfusion bath for
10 to 15 min prior to the application of 1 M epinephrinements by phalloidin did not significantly affect EPI-
induced hyperalgesia (p  0.05; Figure 1D). None of the completely prevented the potentiation of TTX-R INa (Fig-
ure 1E). In contrast, the same treatment did not affect theagents that affect actin—either disrupting or stabilizing
it—had an effect, by itself, on nociceptive threshold (all potentiation of TTX-R INa by PGE2 (Figure 1F), consistent
with the lack of effect of latrunculin A on PGE2 hyperalge-p  0.05; Figures 1A, 1B, and 1D).
Epinephrine and PGE2 produce hyperalgesia, at least sia. Latrunculin by itself had no effect on TTX-R INa (data
not shown).in part, by increasing peak inward current of the tetrodo-
toxin-resistant sodium current (TTX-R INa) and shifting
its activation to more negative membrane potentials Microtubules
To examine the role of microtubules in hyperalgesiathrough activation of their respective GPCRs and subse-
quent PKA signaling (Khasar et al., 1999a; Gold et al., induced by direct-acting agents, we injected rat hind-
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Figure 2. Role of Microtubules in Hyperalge-
sic Signaling
(A) The effect of disrupting microtubules with
nocodazole (EPINDZ; n 6), Colcemid (EPI-
COL; n  6), or vincristine (EPIVIN; n  6)
on mechanical hyperalgesia induced by the
direct-acting agent epinephrine (EPI; n  16).
(B) The effect of disrupting microtubules with
NDZ, COL, or VIN on mechanical hyperalge-
sia induced by the direct-acting agent prosta-
glandin E2 (PGE2; n  16). Values of n for
PGE2NDZ, PGE2COL, and PGE2VIN are
as with EPI same agent in (A); baseline paw
withdrawal threshold (111.5  0.6, g  SEM)
was not affected by the microtubule-dis-
rupting agents nocodazole (NDZ; n  18),
Colcemid (COL; n  12), or vincristine (VIN;
n  12).
(C) Dose-response relation of effects of Col-
cemid on hyperalgesia induced by EPI (n 
6 for each dose) and PGE2 (n  6 for each
dose).
(D) Stabilization of microtubules by a prior
injection of rat paws with the microtubule sta-
bilizer Taxol blocked the attenuating effect of
the microtubule disruptor Colcemid on epi-
nephrine-induced hyperalgesia (TAXCOL
EPI; n  6). The stabilizer was injected 1 hr
preceding the disruptor. Injection of the dis-
ruptor was followed after 30 min by an injec-
tion of epinephrine (EPI; n  12). Taxol by
itself had no effect on EPI- (EPITAX; n 
12) or PGE2-induced hyperalgesia (not
shown; n  6) or on baseline paw withdrawal
threshold (TAX; n  18).
(E) Disrupting microtubules blocks the in-
crease in the TTX-resistant sodium current
caused by epinephrine in whole-cell patch-
clamp experiments. After seal formation and
patch rupture, cells were perfused with either
5 M Colcemid in normal bath (colcemid, n
5) or bath alone (control, n  5). After 10 to
15 min, sodium currents were monitored and
1 M EPI was perfused into the bath for
3 min starting at time 0. The increase in TTX-R INa caused by epinephrine was significantly attenuated by treatment with Colcemid (p  0.05,
two-way repeated measures ANOVA).
In (A)–(D), all injections were made intradermally into the dorsum of the hindpaws. Each agent (disruptor or stabilizer) was injected 30 min
preceding the administration of EPI or PGE2 at the same site. Data is expressed as percentage change in the nociceptive threshold in grams
(%  SEM). (*p  0.0001; one-way ANOVA and Fisher’s PLSD post hoc test; NS  not significant).
paws with the microtubule-disrupting drugs nocoda- sia by Colcemid (p  0.0001; Figure 2D). Taxol alone
slightly but significantly enhanced hyperalgesia inducedzole, Colcemid, or vincristine prior to injection of EPI
and PGE2. All three disruptors significantly antagonized by EPI (p  0.05; Figure 2D) and by PGE2 (data not
shown). None of the agents that affect microtubules—EPI-induced hyperalgesia (all p 0.0001; Figure 2A) but
had no effect on PGE2-induced hyperalgesia (all p  disrupting or stabilizing—had an effect on baseline noci-
ceptive threshold (all p  0.05; Figures 2A and 2B).0.05; Figure 2B). We also injected Colcemid at several
doses in order to confirm that the standard dose was We also tested whether the in vitro potentiation of
TTX-R INa by epinephrine was dependent on intact micro-appropriate. Colcemid (1 ng to 1 g per 2.5 l) had a
clear dose-response relationship in its effect against tubules. Exposure of cultured DRG neurons to 5 M
Colcemid in the perfusion bath for 10 to 15 min prior toEPI-induced hyperalgesia, while at no dose did it have
an effect on either baseline nociception or PGE2-induced the application of 1 M epinephrine completely pre-
vented the potentiation of TTX-R INa (Figure 2E). Col-hyperalgesia (Figure 2C). To provide more evidence that
the inhibition of EPI-induced hyperalgesia by nocoda- cemid by itself had no effect on TTX-R INa (data not
shown).zole, Colcemid, and vincristine was due to microtubule
disruption, we tested whether Taxol could prevent the
block of EPI hyperalgesia by Colcemid. We found that Intermediate Filaments
To examine the role of intermediate filaments in hyperal-administration of Taxol 1 hr preceding injection of Col-
cemid, followed after 30 min by an injection of EPI, gesia induced by direct-acting agents, we evaluated
the effect of the intermediate filament-disrupting drugsignificantly prevented the attenuation of EPI hyperalge-
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PHA-FITC. In control cells (Figure 4A), F-actin was seen
in DRG neurons as a submembranous circular network
of compact bundles lining the inside of the plasma mem-
brane and as a delicate network extending continuously
through the cytoplasm in nonneuronal cells. Neurites
were also strongly stained. In cells that had been treated
with cytochalasin D for 15 min, actin staining became
diffuse with punctate aggregates in the cytoplasm (Fig-
ure 4B). After 1 hr of cytochalasin D treatment, neurites
were no longer stained clearly and cell morphology had
become more rounded (Figure 4C). DRG neurons were
also treated with 5 M nocodazole (or DMSO as control)
for 30 min and 1 hr, fixed, and stained with 	-tubulin
antibody. In untreated neurons, microtubules formed a
fine filamentous structure located in the neurite pro-
cesses and the cytoplasm surrounding the nucleus (Fig-
ure 4D). Cells treated for 30 min with nocodazole showed
a marked depolymerization of the microtubule network,
where peripheral rings were fragmented or replaced with
short and numerous straight bundles filling the central
domains of the cytoplasm of all cell types (Figure 4E).
After 1 hr, microtubule staining was uniform throughout
the cytoplasm and was absent in the neurites (Figure
4F). Colcemid also disrupted microtubules in cultured
DRG neurons using the same protocol (data not shown).
Finally, cultures of DRG neurons were treated with 4
mM acrylamide (or PBS as control) for 30 min, fixed,
and stained with an antibody against high and medium
molecular weight neurofilament (NF-HM). Neurofila-
ment immunoreactivity in control DRG cells showed cir-
Figure 3. Role of Intermediate Filaments in Hyperalgesic Signaling cular and compact bundles along the outer edge of the
(A) The effect of intermediate filament disruption using acrylamide cell body and intense staining in the processes (Figure
on percentage change in nociceptor threshold in epinephrine- (EPI, 4G). Cells treated with acrylamide showed a marked
n  16; EPI  ACR, n  12) or prostaglandin E2- (PGE2, n  16; depolymerization of the neurofilament network presentPGE2  ACR, n 6) induced hyperalgesia. Baseline paw withdrawal
in the cell body of the neurons. The peripheral ring wasthreshold (113.9  0.9, g  SEM) was not affected by acrylamide
fragmented and straight bundles accumulated in thealone (ACR; n  18). (*p  0.0001; one-way ANOVA and Fisher’s
PLSD post hoc test or Student’s t test; NS  not significant). central parts of the cell (Figure 4H).
(B) Dose-response relation of effects of acrylamide on hyperalgesia
induced by EPI (n  6 for each dose) and PGE2 (n  6 for each Hyperalgesic Primingdose).
For up to a month after recovery from carrageenan-
induced hyperalgesia, rats are sensitized to PGE2, which
then produces a markedly prolonged hyperalgesic state
acrylamide on hyperalgesia induced by EPI or PGE2. in a phenomenon referred to as hyperalgesic priming
While acrylamide significantly antagonized EPI-induced (Aley and Levine, 1999). PGE2-induced hyperalgesia dur-
hyperalgesia (p  0.0001), it had no effect on PGE2 hy- ing this primed state is mediated by both PKA (Aley and
peralgesia (p0.05; Figure 3A). As with latrunculin A and Levine, 1999) and PKC (Aley et al., 2000), rather than
Colcemid, acrylamide demonstrated a dose-response by PKA alone, which mediates PGE2 hyperalgesia in the
relationship in its effect on EPI-induced hyperalgesia naive rat (Aley et al., 2001). To test the hypothesis that
but did not affect PGE2-induced hyperalgesia or baseline PGE2 in the primed state produces hyperalgesia by the
nociception at any dose (Figure 3B). Acrylamide alone same signaling mechanisms as EPI, namely by PKA,
did not significantly affect baseline nociceptive thresh- PKC, and ERK (Aley et al., 2001; Dina et al., 2001a),
old (p  0.05; Figures 3A and 3B). we tested whether ERK inhibitors will also inhibit PGE2
hyperalgesia in the primed state. Hyperalgesia, tested
4 hr after injection of PGE2 in carrageenan-pretreatedComparison with In Vitro Effects
of Cytoskeletal Disruptors rats, was significantly inhibited by PD98059 and U 0126,
inhibitors of MEK (which is upstream of ERK) (both p To confirm that the skeletal disruptors produce disrup-
tion in the same time frame as their effects in behavioral 0.0001; Figure 5B). PGE2-induced hyperalgesia was not
inhibited by ERK inhibitors in control rats, i.e., in ratsand electrophysiology studies, we used immunocyto-
chemistry and confocal microscopy to visualize the cy- that had not been previously treated with carrageenan
(p  0.05; Figure 5C). We then tested the hypothesistoskeleton of cultured DRG neurons (1 day in vitro) that
were treated with a representative disrupting agent for that the prolonged hyperalgesia induced by PGE2 in
hindpaws previously treated with carrageenan is depen-each of the three components of the cytoskeleton. Cells
were treated with 10 M cytochalasin D (or DMSO vehi- dent on the cytoskeleton. After a 96 hr recovery from
carrageenan-induced hyperalgesia (Figures 5A and 5D,cle as control) for 15 min or 1 hr, fixed, and stained with
Neuronal Cytoskeleton and Intracellular Signaling
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Figure 4. Effect of Cytoskeletal Disruptors in
DRG Neurons In Vitro
(A–C) Actin staining was performed with PHA-
FITC on (A) control cells, (B) cells treated with
cytochalasin D (10 M) for 15 min, or (C) cells
treated with CD (10 M) for 1 hr. Staining for
filamentous actin is associated primarily with
the membrane in untreated cells and is in-
creasingly diffuse throughout the cytoplasm
in cytochalasin-treated cells. Nonneuronal
cells are also lightly labeled. Each experiment
was repeated at least twice, and the staining
was done on glass coverslips in duplicates.
Negative controls with unlabeled PHA and
PHA-FITC showed no staining (not shown).
(D–F) Microtubule staining was performed
with 	-tubulin antibody on (D) control cells,
(E) cells treated with nocodazole (NDZ) (5M)
for 30 min, and (F) cells treated with NDZ (5
M) for 1 hr. Each experiment was repeated
at least twice and the staining was done on
glass coverslips in duplicates. Negative con-
trols with mIgG1/IgG-FITC showed no stain-
ing (not shown).
(G and H) Neurofilament staining was per-
formed with high and medium molecular
weight neurofilament (NF-HM) antibody on
(G) control cells or (H) cells treated with acryl-
amide (4 mM) (ACR) for 30 min. Each experi-
ment was repeated at least twice and staining
was done on glass coverslips in duplicates.
Negative controls treated with mIgG1/IgG-
FITC showed no staining (not shown).
left), intradermal injection of PGE2 resulted in a hyperal- Role of the Cytoskeleton in Second
Messenger Signalinggesia lasting up to 24 hr (Figure 5D, right). When the
actin disruptor Lat A was injected 30 min before PGE2 We then asked whether the hyperalgesic effects of acti-
vating the PKA, PKC, or ERK second messenger sys-in the same paradigm, hyperalgesia seen at 0.5, 4, and
24 hr after PGE2 was significantly inhibited (p  0.0001; tems, independent of receptor activation, were also de-
pendent on the cytoskeleton. The hyperalgesia causedFigure 5D, right).
Neuron
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Figure 5. Role of MEK and Actin Filaments
on Hyperalgesic Priming
(A) Low-dose carrageenan (5 l of 1% solu-
tion; n  96) intradermally injected into rat
hindpaws induces hyperalgesia that resolves
within 96 hr. Subsequent injection of PGE2 at
the same site produces a hyperalgesia that
lasts up to 24 hr, a phenomenon referred to
as hyperalgesic priming.
(B) Hyperalgesia at 4 hr post-PGE2 in carra-
geenan-primed rats (n  12) was blocked by
the inhibitors of MEK, PD 98059 (n  6) or U
0126 (n  6), neither of which had any effect
on nociceptive threshold when given alone
(n  6 each). PGE2 was injected at least 96
hr after carrageenan, when carrageenan-
induced hyperalgesia had worn off (left).
(C) In untreated, carrageenan-naive rats, the
MEK inhibitors PD 98059 (n  6) and U 0126
(n 6) had no effect on normal PGE2-induced
hyperalgesia.
(D) The effect of disrupting actin filaments
with latrunculin A (LatA; n 8) on the duration
and intensity of hyperalgesia induced by
prostaglandin E2 (PGE2; n  8) after recovery
from CARR-induced hyperalgesic priming.
PGE2 was injected at least 96 hr after carra-
geenan, when carrageenan-induced hyperal-
gesia had worn off (left). The long-lasting
PGE2-induced hyperalgesia in carrageenan-
primed rats was significantly reduced by pre-
treatment with latrunculin A at all time points
(right).
Data are expressed as percentage change in
nociceptive threshold in grams (%  SEM)
(*p  0.0001; one-way ANOVA followed by
Fisher’s PLSD post hoc test; NS  not signif-
icant).
by injection of the membrane-permeable PKA agonist pendent on the cytoskeleton—an effect associated with
a change from dependence on PKA alone to depen-8-bromo-cAMP and the catalytic subunit of PKA was
dence on PKC and ERK as well (Aley et al., 2000).not affected by prior treatment with cytochalasin D, Col-
Since the peripheral terminals of primary afferent noci-cemid, or acrylamide (Figures 6A and 6B). In contrast,
ceptors are very thin and their relative density in peri-the hyperalgesia induced by injection of the PKC acti-
pheral tissue low, it is not possible to directly assessvator, 
-RACK, and the ERK activator, active MEK, was
cytoskeletal function in these terminals. However, non-completely inhibited by each of these three cytoskeletal
specific effects of cytoskeleton disruptors are unlikely todisruptors (Figures 6C and 6D). Therefore, hyperalgesia
account for our findings for several reasons: (1) multiplecaused by independent activation of PKC or ERK is
disruptors of each element produced the same effect, (2)dependent on an intact cytoskeleton, while that caused
in normal rats disruptors have no effect on hyperalgesiaby independent activation of PKA is not.
induced by the direct-acting agent PGE2, while (3) they
do block PGE2-induced hyperalgesia in carrageenan-
Discussion primed rats, (4) sensitization of TTX-R INa by EPI but
not PGE2 in cultured DRG neurons is also affected by
We examined the role of cytoskeletal elements in or- cytoskeletal disruption, and (5) the time course for dis-
ganizing transduction mechanisms for the production of ruption of hyperalgesia in vivo is similar to the time
hyperalgesia by inflammatory mediators that act directly course for disruption of the cytoskeletal elements seen
on the peripheral terminals of primary afferent nocicep- in vitro. Since it has previously been shown in other
tors through G protein-coupled receptors (GPCRs). In model systems that stabilizers of cytoskeleton can pro-
normal male rats, intact actin filaments, microtubules, tect against the effect of disruptors (Karbowski et al.,
and intermediate filaments are all necessary for EPI- 2001), we also determined that cytoskeleton stabilizers
induced hyperalgesia, while PGE2-induced hyperalgesia could block attenuation of EPI hyperalgesia produced
appears to be independent of the state of the cytoskele- by disruptors; another indication of the specificity of
ton. In addition, we demonstrate plasticity in this cy- action of the disruptors. Effects of the cytoskeletal dis-
toskeletal dependence. Thus, following exposure to ruptors acting on other cells present in dermal tissue is
also unlikely, due to the fact that EPI clearly acts directlycarrageenan, PGE2-induced hyperalgesia becomes de-
Neuronal Cytoskeleton and Intracellular Signaling
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Figure 6. Role of Cytoskeleton in Second
Messenger Signaling
The effect of disrupting the cytoskeletal ele-
ments, actin filaments, microtubules, and in-
termediate filaments using cytochalasin D
(CD; n  24), Colcemid (COL; n  24), and
acrylamide (ACR; n  24) on hyperalgesia in-
duced by (A) PKA activator 8-bromo-cAMP
(n 16); (B) protein kinase A catalytic subunit
(PKA-CS; n  18); (C) PKC activator 
-
RACK (n  18); or (D) MAPK activator active
MEK (MEK; n  18).
Data are shown as percentage change in the
nociceptive threshold in grams (%  SEM).
(*p  0.0001; one-way ANOVA followed by
Fisher’s PLSD post hoc test; NS  not signif-
icant).
on the nociceptor terminal (Khasar et al., 1999b) and cytoskeleton completely eliminated EPI hyperalgesia
without affecting PGE2 hyperalgesia. Cytoskeletal dis-given the consistency of the effects on isolated DRG
neurons in vitro with the behavioral results. ruption also completely eliminated PGE2-induced hyper-
algesia after carrageenan-induced hyperalgesic prim-Many plasma membrane GPCRs, such as the
2-adrenergic receptor, use cytoskeletal proteins to es- ing, a setting in which PGE2 hyperalgesia is dependent
on PKC and ERK in addition to PKA. These observa-tablish their juxtaposition to intracellular second mes-
senger signaling pathways (Bloch et al., 2001; Calaghan tions suggest that actin microfilaments, microtubules,
and intermediate filaments are all needed for the func-et al., 2001; Cong et al., 2001; Diviani and Scott, 2001;
Fraser et al., 2000; Jasper et al., 1995; Vouret-Craviari tion of a PKA/PKC/ERK second messenger signaling
complex, possibly by anchoring it in the proximity of theet al., 1998; Wang et al., 2000). Therefore, one function
of the subcytoplasmic membrane cytoskeleton, which 2-adrenergic receptor. Hyperalgesia induced by direct
activation of PKC and ERK was also attenuated byis composed of microfilaments, microtubules, and inter-
mediate filaments (Bershadsky and Vasiliev, 1988; Jan- disruption of cytoskeleton, similar to the previously de-
scribed cytoskeletal dependence of PKC and ERK sig-mey, 1998; Schliwa, 1987), may be the organization of
GPCR signaling, including the manifestation of plasticity naling in other systems (Disatnik et al., 2002; Pawlak
and Helfman, 2002; Toker, 1998).in the coupling between receptors and second messen-
gers. While EPI and PGE2 both signal through PKA, only While we see a decreased hyperalgesia following
acute administration of disruptors of cytoskeleton, overthe PKA activation induced by EPI is disrupted by cy-
toskeleton, suggesting that the two GPCRs are coupled longer periods of time, some of the disruptors cause
hyperalgesia (Aley et al., 1996). Thus, humans receivingdifferently to PKA. This could be explained by the exis-
tence of separate second messenger signaling compart- vincristine as cancer chemotherapy can develop a pain-
ful peripheral neuropathy (Apfel and Kessler, 1996; Pe-ments that couple to different GPCRs (El Far and Betz,
2002; Milligan and White, 2001; Sweatt, 2001), such that trini et al., 1999; Valdivieso et al., 1981), an effect that
we have modeled in the rat (Aley et al., 1996; Tanner etplasticity in nociceptors following, for example, carra-
geenan-induced hyperalgesic priming may be mediated al., 1998a, 1998b; Topp et al., 2000). These opposite
effects of acute and chronic administration of disruptorsby changing the coupling of receptors to second mes-
senger pathways mediating hyperalgesia (Crouch et al., of cytoskeleton on the function of primary afferent noci-
ceptors may involve differential impacts on, for example,1997; Evans et al., 1995; Ferguson, 2001; Kelly and
Wagner, 1999), including their dependence on the cy- protein synthesis or axonal transport, and require further
analysis.toskeleton.
While both EPI and PGE2 hyperalgesia depend on Although the cytoskeleton has an important role in
several aspects of neuronal function, its role in sensoryPKA, disruption of each of the three elements of the
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disruptors [Spector et al., 1989]), PD 98059 (2-amino-3-methoxy-transduction has only recently been examined (Huang
flavone; selective MAP kinase kinase, MEK inhibitor [Kultz et al.,et al., 1995; Mannsfeldt et al., 1999). It has been sug-
1998]), and U 0126 ([1,4-Diamino-2, 3-dicyano-1, 4-bis (2-aminophe-gested that cytoskeletal elements may contribute to me-
nylthio) butadiene]; specific inhibitor of MEK 1/2 [DeSilva et al.,
chanical transduction in sensory neurons (Mannsfeldt 1998]) were obtained from Calbiochem-Novobiochem, La Jolla, CA.
et al., 1999). A general feature of mechanosensory trans- cAMP-dependent protein kinase A-catalytic subunit (PKA-CS), a 38
kDa serine/threonine protein kinase (Slice and Taylor, 1989; Uhlerduction is the presence of a transduction channel that
et al., 1986; Walsh et al., 1968), was obtained from New Englandis thought to be anchored to the cytoskeleton at intracel-
BioLabs (Beverly, MA), and HDAPIGYD-protein kinase C activator,lular sites (Alenghat and Ingber, 2002; Shafrir and For-
pseudo  RACK (receptor for activated C kinase; 
-RACK [Dorn etgacs, 2002) and to an extracellular structure through
al., 1999]) was synthesized by SynPep Corp. (Dublin, CA). Dominant-
which forces are applied (Chalfie, 1997; Gillespie and active (MEK) recombinant MAP kinase (MEK1) (Alessi et al., 1995;
Walker, 2001; Tavernarakis and Driscoll, 1997). Never- Saxena et al., 1999) was obtained from Upstate Biotechnology (Lake
Placid, NY). All chemicals were of reagent grade.theless, the cytoskeletal disrupting or stabilizing agents
Epinephrine (4 mg/ml) was dissolved in distilled water with anused in the present study did not affect nociceptive
equivalent amount of ascorbic acid (Parkkinen et al., 1996) justbaseline in spite of the fact that all the cytoskeleton-
before it was used and was kept on ice in subdued lighting condi-disrupting agents markedly attenuated mechanical hy-
tions (Dina et al., 2001a; Khasar et al., 1999b). Final concentration
peralgesia and disrupted the cytoskeleton in dorsal root of epinephrine was 100 g/2.5 l in distilled water. A stock solution
ganglion neurons in vitro. Mechanical transduction in of PGE2 (4 mg/ml) was made by dissolving it in 10% ethanol in
normal saline; further dilution to 100 ng/2.5 l was made by additionvertebrate sensory neurons is poorly understood; per-
of saline. Final concentration of ethanol was 1%. Cytochalasin Bhaps other structural elements are important for this
and D, phalloidin, nocodazole, Colcemid, PD 98059, and U 0126process in nociceptors.
were dissolved in 10% dimethyl sulfoxide (final concentration ofIn summary, the present study provides evidence that
DMSO 1%). Vincristine was dissolved in normal saline to an initial
signaling for hyperalgesia induced by epinephrine but concentration of 1 mg/ml and diluted in saline to 1 g/2.5 l for
not prostaglandin E2 is dependent on the cytoskeleton intradermal injections. Taxol (1 mg/ml) was formulated at a concen-
tration of 1 mg/ml in a vehicle comprising absolute ethanol andin the peripheral terminal of the primary afferent noci-
Cremophor EL as previously described (Dina et al., 2001b). Finalceptor, and that hyperalgesia caused directly by PKA
Taxol concentration of 1g/2.5l was made in normal saline-dilutedis not dependent on the cytoskeleton, while that by PKC
Cremophor vehicle. Stock solutions of acrylamide and 8-Br-cAMPand ERK is. Also, when primed by carrageenan, PGE2 were made in normal saline and diluted in distilled water before
signaling also becomes dependent on the cytoskeleton use. Test agents were administered using a 30-gauge hypodermic
as well as on ERK. This long-lasting consequence from needle. Carrageenan (Chang, 1975; Dawson et al., 1991; Di Rosa,
1972; Sammons et al., 2000) solution (1% w/v) was made in normalexposure to an inflammogen, as well the earlier finding
saline and injected intradermally (5 l) into the dorsum of each pawthat chronic disruption of microtubules by vincristine
using a 27-gauge needle (Aley et al., 2000). Stock solutions (1 g/l)leads to a chronic hyperalgesia (Aley et al., 1996), sug-
of inhibitors were stored at 20C. Final solutions of Taxol, PDgest that the cytoskeleton may play a role in the develop-
98059, U 0126, acrylamide, and Lat A were stored in the dark at 4C
ment of chronic pain. Significantly, all differences in to prevent photooxidation. All injections were by the intradermal
dependence on the cytoskeleton correlated with depen- route in the hindpaw as previously described (Khasar et al., 1995;
Taiwo et al., 1989). Stock solutions of PKA-CS (100 U/l), 
-RACKdence on PKC and ERK. This differential involvement of
(1 g/l), and active MEK (1 U/l) were made in physiological saline.the cytoskeleton in peripheral hyperalgesias may have
Final concentrations of PKA-CS (10 U/2.5 l), 
-RACK (1 g/2.5implications for the treatment of inflammatory pain.
l), and active MEK (1 U/2.5 l) were made in saline. Stock solutions
of PKA-CS and 
-RACK were stored at20C while stock solutions
Experimental Procedures
of recombinant active MEK were stored at 70C. Cytoskeletal dis-
ruptor drugs and stabilizers were injected at a concentration of 1
Animals
g/2.5 l except where otherwise stated. To evaluate the effect of
Experiments were performed on male Sprague-Dawley rats (200–
cytoskeletal disruptors or stabilizers on hyperalgesic agents, the
280 g; Bantin and Kingman, Fremont, CA), housed in the Animal
disruptor or stabilizer was injected alone 30 min before the hyperal-
Care Facility of the University of California, San Francisco. In all
gesic agent. Measurements of the effect of hyperalgesic agents in
sets of experiments, adult rats of the same age were used. Food
the presence of the cytoskeletal drug were taken after a further
and water were available ad libitum. Care and use of animals con-
30 min.
formed to NIH guidelines. The UCSF Committee on Animal Research
approved experimental protocols. All efforts were made to minimize
both the suffering and number of animals used. Mechanical Nociceptive Threshold Testing
The nociceptive flexion reflex was quantified using the Randall-
Selitto paw pressure test (Randall and Selitto, 1957) (Analgesymeter,Drugs: Preparation and Administration
The drugs used in this study were from Sigma (St. Louis, MO) unless Stoelting, Chicago, IL) in which a linearly increasing mechanical
force is applied to the dorsum of the rat’s hindpaw (Taiwo et al.,otherwise noted: hyperalgesic inflammatory mediators epinephrine
()-bitartrate (EPI; 4[1-Hydroxy-2-(methylamino)ethyl]-1,2-benzen- 1989). The nociceptive threshold was defined as the force in grams
at which the rat withdrew its paw. The protocols for this procedureediol) and prostaglandin E2 (PGE2; ([5Z,11	,13E,15S]-11,15-Dihy-
droxy-9-oxoprosta-5,13-dienoic acid); cytochalasin B and D (CB, have been previously described (Taiwo et al., 1989). In the week
preceding the experiments, rats were familiarized with the testingCD; fungal toxins and actin microfilament disruptors [Sasaki et al.,
1995]); phalloidin (PHA; fungal toxin and actin microfilament stabi- procedure at 5 min intervals for a period of 1 hr per day for 3 days.
Baseline paw withdrawal threshold was defined as the mean of sixlizer); nocodazole (NDZ; R 17934; Methyl-(5-[2-Thienyl-carbonyl]-
1N-Benzimidazol-zyl)-carbamate; microtubule disruptor); Colcemid readings before test agents were injected. Each paw was treated
as an independent measure and each experiment was performed(COL; N-Deacetyl-N-methylcolchicine; microtubule disruptor); vin-
cristine (VIN; microtubule disruptor); paclitaxel (Taxol; TAX; microtu- on a separate group of rats. Except where stated, rats were treated
with only one agonist and/or antagonist injected peripherally by thebule stabilizer [Derry et al., 1995]); acrylamide (intermediate filament
disruptor); 8-bromoadenosine 3,5-cyclic monophosphate (8-Br- intradermal route. Measurements of nociceptive thresholds were
taken 0.5 hr after the administration of the hyperalgesic inflammatorycAMP); and carrageenan (CARR; an inflammatory agent). Latrun-
culin A and B (Lat A and Lat B; marine toxins and actin microfilament mediators except in primed paws when measurements were taken
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0.5, 4, and 24 hr after PGE2, which was injected after a 4–5 day were permeabilized with 0.1% Triton X-100 in PBS buffer type 1 for
5 min at room temperature. Cells were stained for 45 min at roomrecovery from carrageenan treatment. It has been shown in previous
studies that agents injected using the protocol described exert a temperature with FITC-phalloidin (0.5 mg/ml, Sigma) diluted in PBS
buffer type 1  0.1% Triton X-100. Nonspecific PHA-FITC bindingperipheral rather than central action (Khasar et al., 19995, 1999a).
All behavioral testing was done between 10 am and 4 pm. Because was performed by pretreating fixed, permeabilized cells with unla-
beled phalloidin prior to addition of FITC-labeled phalloidin. Cellsthey are less membrane permeable, injections of protein kinase A
catalytic subunit (PKA-CS), protein kinase  agonist (
-RACK), and were washed in supplemented PBS buffer type 1 and incubated for
10 min at room temperature with propidium iodide (1 mg/ml; Sigma)active MEK were always preceded by administration of 2.5 l of
distilled water in the same syringe to produce hypo-osmotic shock, for nuclear localization. For tubulin and neurofilament staining, the
thereby enhancing cell membrane permeability (Khasar et al., 1995; cells were washed in PBS and fixed in 2% PFA for 10 min at room
Lepers et al., 1990; Taiwo and Levine, 1989; Tsapis and Kepes, temperature. Permeabilization and blocking steps were performed
1977; West and Huang, 1980; Widdicombe et al., 1996). PKA-CS, by incubating the coverslips with supplemented PBS buffer type 2

-RACK, active MEK, and protein kinase inhibitors were separated (PBS  5% of normal goat serum  1 mM CaCl2  1 mM MgCl2 
in each case from the distilled water by drawing up a small air 0.1% Triton X-100) for 5 min at room temperature. Cells were stained
bubble (1 l) into the syringe after drawing up the protein kinase overnight at 4C with mouse monoclonal antibodies against
agonist or inhibitor but before drawing up the distilled water. 	-tubulin (1:2000; Sigma) or high and medium molecular weight
neurofilament (NF-HM, 5 g/ml; Zymed, South San Francisco, CA)
diluted in supplemented PBS buffer type 2. For negative control,Pharmacological Interventions
isotype-matched control antibody (purified mouse immunoglobulinTo determine the role of cytoskeletal integrity on mechanical hyper-
IgG1, Sigma) was used as primary antibody (5g/ml). The coverslipsalgesia, we evaluated the effect of microfilament-, microtubule-, and
were then washed three times with PBS buffer type 2 and cellsintermediate filament-disrupting and microfilament- and microtu-
were stained with fluorescent-conjugate F(ab’)2 fragment goat anti-bule-stabilizing agents (neurofilament stabilizers are not available)
mouse IgG secondary antibody (HL) (Sigma) for 30 min at roomusing established models of EPI- and prostaglandin E2-induced hy-
peralgesia. The cytoskeletal agents, with and without EPI (Khasar temperature. Cells were washed in PBS buffer type 2 and incubated
et al., 1999b) or prostaglandin E2 (PGE2) (Aley et al., 1998, 2000; Aley with 1 g/ml propidium iodide to confirm their presence in negative
and Levine, 1999), were injected as described previously (Khasar control experiments. The coverslips were mounted under Vecta-
et al., 1995, 1999b). The doses of the agonists were selected on the shield (Vector Laboratories, Burligame, CA) and observed using a
basis of dose-response studies (Khasar et al., 1995, 1999b), while Bio-Rad MRC 1000 laser scanning confocal microscope, a Zeiss
the dose of the cytoskeletal agents (1 g/2.5 l) was the same dose Axiovert 100 microscope, or a Zeiss 100 Plan-Apochromat oil
used for a number of antagonists shown in previous studies to immersion objective for clearer localization.
produce a significant attenuation of EPI- or PGE2-induced hyperal-
gesia in rats (Aley et al., 1998; Dina et al., 2000, 2001a, 2001b; Khasar
et al., 1995, 1999a, 1999b; Taiwo and Levine, 1991). Patch-Clamp Electrophysiology
To examine the role of cytoskeletal disruption in the epinephrine-
induced increase in the tetrodotoxin-resistant sodium current (TTX-Hyperalgesic Priming
R INa), whole-cell patch-clamp recordings were made in isolatedIn hyperalgesic priming studies (Aley et al., 2000), intradermal injec-
DRG neurons. Small-diameter (20–30 m) neurons that showed ations of the agonists and/or antagonists for cytoskeletal drugs were
peak TTX-R INa of at least 1 nA were chosen for study. Bath solutionapplied to the same site to which a low dose of the priming agent,
continuously perfused the recording chamber at 1–2 ml/min andcarrageenan (5 l of 1% solution), had been injected 5 days earlier.
drugs were applied via the bath. Experiments were performed atCarrageenan-induced hyperalgesia was established within 0.5–1 hr
following injection, maximal at 2–4 hr, and completely resolved in room temperature (21C–24C).
72–96 hr (Aley et al., 2000). Whole-cell patch-clamp recordings were performed using an Axo-
patch 200B amplifier with pClamp6 acquisition and stimulation pro-
grams (Axon Instruments, Foster City, CA). Data were low-passCell Culture
filtered at 5 kHz and acquired at 20 kHz. Voltage-clamp experimentsPrimary cultures of adult rat DRG neurons were prepared as de-
were performed with 1 to 5 M electrodes filled with (in mM) 140scribed previously (Gold et al., 1996). Briefly, male Sprague-Dawley
CsCl, 10 NaCl, 0.1 CaCl2, 2 MgCl2, 11 EGTA, 10 HEPES, 2 Mg-ATP,rats (150–250 g) (Bantin and Kingman, Fremont, CA) were anesthe-
and 1 Li-ATP; pH was adjusted to 7.2 with Tris-base. Bath solutiontized with Na-pentobarbitol (60 mg/kg, i.p.). Lumbar DRGs (L1–L6)
contained (in mM) 35 NaCl, 30 tetraethylammonium chloride, 65were removed bilaterally, enzymatically digested with collagenase
choline chloride, 0.1 CaCl2, 5 MgCl2, 10 HEPES, and 10 glucose; pHand trypsin, mechanically dispersed, and plated onto coverslips as
was adjusted to 7.4 with NaOH and osmolarity adjusted to 325previously described (Gold and Levine, 1996). Each preparation of
mOsm with sucrose. Tetrodotoxin (TTX, 50 nM) was added to theneurons included the DRG removed from a single rat. Cells were
bath solution. Capacitance and series resistance was compensatedmaintained in minimal essential medium (MEM) supplemented with
(80%), and leak subtraction was performed with a P/4 protocol.10% fetal bovine serum, 1000 units per ml each of penicillin and
After obtaining a current-voltage (I-V) relationship for TTX-R INa, astreptomycin, vitamins, and 50 ng/ml nerve growth factor (NGF,
mouse 7S, Boehringer-Manheim) (McCarter et al., 1999; Winter, test pulse was applied from a holding potential of 60 mV every 20
1987) before they were used for confocal microscopy and in vitro s to monitor the amplitude of TTX-R INa during the experiment. A
patch-clamp electrophysiology. Cells were used during the first 24 voltage that produced approximately half-maximal current activa-
hr after plating. tion was used for the test pulse because hyperalgesic agents pro-
duce the greatest increase in TTX-R INa at this part of the I-V curve
(Gold et al., 1996). Latrunculin A and Colcemid or control solutionIn Vitro Drug Treatment and Fluorescence Microscopy
were applied via bath perfusion for 10 to 15 min before applicationCultured DRG neurons were incubated with cytoskeletal disruptors
of 1 M EPI. Currents were averaged into 1 min bins and normalizedat concentrations and for incubation times chosen to mimic in vivo
for each cell to the mean amplitude of the nine responses immedi-administration. Cytochalasin D, diluted in DMSO, was used at a final
ately before epinephrine application.concentration of 10 M; nocodazole, diluted in DMSO, was used at
5 M; and acrylamide, diluted in phosphate-buffered saline (PBS),
was used at 4 mM. Final concentration of DMSO, added to the cells,
Data Analysiswas 0.05%–0.2%, which alone had no effect on cell behavior or
Group data are presented as mean  SEM and comparisons be-organization of the actin cytoskeleton (Cramer et al., 2002).
tween groups were done using Student’s t test or analysis of vari-For actin staining, the cells were plated on coverslips, washed in
ance (ANOVA) followed by Fisher’s protected Least Significant Dif-PBS, and fixed in 2% paraformaldehyde (PFA) in PBS for 10 min at
ference (PLSD) post hoc test, as appropriate. A probability of p room temperature. After three washes in supplemented PBS buffer
type 1 (PBS  1% BSA  1 mM CaCl2  1 mM MgCl2), the cells 0.05 was considered significant.
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